Marc J van de Vijver

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. pmc Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy
    J Hannemann
    Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Br J Cancer 95:1334-41. 2006
  2. pmc Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
    I F Faneyte
    Department of Pathology, The Netherlands Cancer Institute, Amsterdam
    Br J Cancer 88:406-12. 2003
  3. pmc Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients
    J A van der Hage
    Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands
    Br J Cancer 90:1543-50. 2004
  4. pmc Predicting a local recurrence after breast-conserving therapy by gene expression profiling
    Dimitry S A Nuyten
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 8:R62. 2006
  5. pmc Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 9:R65. 2007
  6. pmc A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer
    Fabien Reyal
    Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 10:R93. 2008
  7. pmc Classification of ductal carcinoma in situ by gene expression profiling
    Juliane Hannemann
    Division of Experimental Therapy, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 8:R61. 2006
  8. pmc Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis
    Jos A van der Hage
    Leiden University Medical Center, Department of Surgery, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Breast Cancer Res 9:R70. 2007
  9. pmc EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
    Alexandra M Pietersen
    Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066X, The Netherlands
    Breast Cancer Res 10:R109. 2008
  10. pmc Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability
    Martin H van Vliet
    Information and Communication Theory Group, Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Mekelweg 4, 2628 CD Delft, The Netherlands
    BMC Genomics 9:375. 2008

Collaborators

Detail Information

Publications26

  1. pmc Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy
    J Hannemann
    Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Br J Cancer 95:1334-41. 2006
    ..Possibly, the difference of the cumulative dose of only 25% between the treatment arms was insufficient to yield a survival difference...
  2. pmc Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
    I F Faneyte
    Department of Pathology, The Netherlands Cancer Institute, Amsterdam
    Br J Cancer 88:406-12. 2003
    ..Proliferation decreases significantly after chemotherapy. ER negativity and a high proliferation index are associated with better response. HER2 status does not predict response, and outcome is not related to tumour response...
  3. pmc Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients
    J A van der Hage
    Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands
    Br J Cancer 90:1543-50. 2004
    ....
  4. pmc Predicting a local recurrence after breast-conserving therapy by gene expression profiling
    Dimitry S A Nuyten
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 8:R62. 2006
    ..Here we have used gene expression profiling by microarray analysis to identify gene expression profiles that can help to predict local recurrence in individual patients...
  5. pmc Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 9:R65. 2007
    ..We examined the histopathological and gene-expression profile of triple-negative tumors to define subgroups with specific characteristics, including risk of developing distant metastases...
  6. pmc A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer
    Fabien Reyal
    Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 10:R93. 2008
    ..we address the following issues: Do these signatures perform similarly? Are there (common) molecular processes reported by these signatures? Can better prognostic predictors be constructed based on these identified molecular processes?..
  7. pmc Classification of ductal carcinoma in situ by gene expression profiling
    Juliane Hannemann
    Division of Experimental Therapy, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 8:R61. 2006
    ....
  8. pmc Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis
    Jos A van der Hage
    Leiden University Medical Center, Department of Surgery, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Breast Cancer Res 9:R70. 2007
    ..Therefore, we studied the effect of adjuvant chemotherapy in young patients with breast cancer in relation to hormone receptor status...
  9. pmc EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
    Alexandra M Pietersen
    Division of Molecular Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066X, The Netherlands
    Breast Cancer Res 10:R109. 2008
    ..This histone mark recruits the BMI1-containing PRC1 that silences the genes marked by PRC2. Based on their role in stem cells, EZH2 and BMI1 have been predicted to contribute to a poor outcome for cancer patients...
  10. pmc Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability
    Martin H van Vliet
    Information and Communication Theory Group, Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Mekelweg 4, 2628 CD Delft, The Netherlands
    BMC Genomics 9:375. 2008
    ..This provides a unique opportunity to employ a substantial dataset to investigate the effects of pooling datasets on classifier accuracy, signature stability and enrichment of functional categories...
  11. pmc SIRAC: Supervised Identification of Regions of Aberration in aCGH datasets
    Carmen Lai
    Bioinformatics Group, Delft University, Delft, The Netherlands
    BMC Bioinformatics 8:422. 2007
    ..Therefore, the identification of DNA amplifications or deletions across tumors may reveal key genes involved in cancer and improve our understanding of the underlying biological processes associated with the disease...
  12. pmc Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
    Marc van de Vijver
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res 9:R68. 2007
    ....
  13. ncbi request reprint Emerging technologies for HER2 testing
    Marc van de Vijver
    Department of Pathology, The Netherlands Cancer Institute, NL 1066 CX Amsterdam, The Netherlands
    Oncology 63:33-8. 2002
    ..While such technologies show great promise, they will at least have to be validated against IHC or FISH before being accepted into routine clinical practice...
  14. ncbi request reprint Gene-expression profiling and the future of adjuvant therapy
    Marc van de Vijver
    Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Oncologist 10:30-4. 2005
    ..com) in breast cancer patients. It is expected that in the coming years an increasing number of novel prognostic and predictive tests will help in guiding the adjuvant systemic treatment of breast cancer and other malignancies...
  15. pmc The diagnosis and management of pre-invasive breast disease: pathological diagnosis--problems with existing classifications
    Marc J van de Vijver
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res 5:269. 2003
    ..If there is doubt about the classification of an intraductal proliferation, a differential diagnosis and the reason for and degree of uncertainty should be given, rather than categorizing a proliferation as atypical...
  16. ncbi request reprint Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer
    Ian F Faneyte
    Department of Experimental Therapy, Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Anticancer Res 24:2931-9. 2004
    ..Multidrug resistance associated proteins MRP1, MRP2 and MRP3 confer in vitro multidrug resistance. We investigated their role in breast cancer resistance to anthracycline-based chemotherapy...
  17. ncbi request reprint Sentinel lymph node biopsy for localised ductal carcinoma in situ?
    P Veronesi
    Division of Breast Surgery, European Institute of Oncology, Via Ripamonti, 435, 20141 Milan, Italy
    Breast 14:520-2. 2005
    ..If the SLN is micrometastatic complete axillary dissection is not unavoidable...
  18. doi request reprint Radiation-associated breast tumors display a distinct gene expression profile
    Annegien Broeks
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 76:540-7. 2010
    ..Approximately 90% of the breast cancers in these patients can be attributed to their radiation treatment, rendering such series extremely useful to determine whether a common radiation-associated cause underlies the carcinogenic process...
  19. doi request reprint Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
    Jorma J de Ronde
    Department of Bioinformatics and Statistics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 119:119-26. 2010
    ..For Luminal(IHC) and triple negative(IHC) tumors, further subdivision into molecular subgroups does not offer a clear advantage in treatment selection...
  20. doi request reprint A conditional mouse model for malignant mesothelioma
    Johan Jongsma
    Department of Molecular Genetics, Cancer Genomics Centre, Centre for Biomedical Genetics, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Cancer Cell 13:261-71. 2008
    ..Interestingly, upon Ink4a loss in the latter mice median survival was significantly reduced and all tumors were highly invasive, suggesting that Ink4a loss substantially contributes to the poor clinical outcome of malignant mesothelioma...
  21. ncbi request reprint A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients
    Hongyue Dai
    Rosetta Inpharmatics LLC, A wholly owned subsidiary of Merck and Co Inc Seattle, Washington, USA
    Cancer Res 65:4059-66. 2005
    ..Our work presented here may contribute a crucial step towards rational design of personalized treatment...
  22. pmc Determination of stromal signatures in breast carcinoma
    Robert B West
    Department of Pathology, Stanford University Medical Center, Stanford, California, USA
    PLoS Biol 3:e187. 2005
    ..Our findings suggest that the host stromal response varies significantly among carcinomas and that gene expression patterns characteristic of soft tissue tumors can be used to discover new markers for normal connective tissue cells...
  23. ncbi request reprint Improving patient care through molecular diagnostics
    Edith A Perez
    Mayo Clinic, Jacksonville, FL 32224, USA
    Semin Oncol 31:14-20. 2004
    ..The use of these systems will allow further development of customized therapies directed toward the particular molecular defects in a given cancer...
  24. ncbi request reprint Current perspectives on HER2 testing: a review of national testing guidelines
    Michael Bilous
    Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
    Mod Pathol 16:173-82. 2003
    ..The key point underlined by this review is that whatever method is used to test for HER2 status, the technology must be validated first, and there must be regular internal and external quality control and quality assurance procedures...
  25. pmc Lung metastasis genes couple breast tumor size and metastatic spread
    Andy J Minn
    Department of Radiation and Cellular Oncology, Center for Molecular Oncology, and Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 104:6740-5. 2007
    ....
  26. ncbi request reprint American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker...